Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Cyclo Therapeutics, Inc. | ex_186177.htm |
| EX-31.2 - EXHIBIT 31.2 - Cyclo Therapeutics, Inc. | ex_186175.htm |
| EX-31.1 - EXHIBIT 31.1 - Cyclo Therapeutics, Inc. | ex_186174.htm |
| 10-Q - FORM 10-Q - Cyclo Therapeutics, Inc. | ctdh20200331_10q.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report on Form 10-Q of Cyclo Therapeutics, Inc. (the “Company”) for the fiscal quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, N. Scott Fine, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: May 15, 2020 |
/s/ N. Scott Fine |
|
|
N. Scott Fine |
|
|
Chief Executive Officer |
|
|
(principal executive, financial and accounting officer) |